promotes production of cortical neurons with morphological deficits (Rooney et al., 2016) . Human induced pluripotent stem cells from RASG12S CS patients differentiate to astroglia more rapidly than wild type (WT) cells. Additionally, RASG12S cells show abnormal astrocyteto-neuron signaling, as do astrocytes in an astrocyte-driven RASG12V mouse model (Krencik et al., 2015) . Interestingly, MRI studies have shown brain white matter (WM) abnormalities in CS patients, suggesting that delayed myelination and/or abnormal myelin contribute to CS developmental delays (Delrue, Chateil, Arveiler, & Lacombe, 2003) .
These studies, together with research relating defective oligodendrocyte function with mental illness (Haroutunian et al., 2014) , suggest that hyperactive RAS in myelinating cells may contribute to CS pathology.
Myelin sheaths are plasma membrane projections of oligodendrocytes that spirally wrap axons and myelin layers become compacted, increasing axon conduction velocity (Bauer, Richter-Landsberg, & Ffrench-Constant, 2009; Franklin and Gallo, 2014) . The Ras-MAPK pathway kinases MEK and ERK regulate several aspects of developmental, injury-induced, and in vitro oligodendrogenesis as well as regulate the number of myelin wraps produced by normal oligodendrocytes (Fyffe-Maricich, Karlo, Landreth, & Miller, 2011; Fyffe-Maricich, Schott, Karl, Krasno, & Miller, 2013; Guardiola-Diaz, Ishii, & Bansal, 2012; Ishii, Furusho, & Bansal, 2013; Xiao et al., 2012) . In contrast, mice expressing the Ras-activating HRasG12V allele in cells of the oligodendrocyte lineage starting at embryonic day 12.5, exhibit myelin decompaction at intraperiod lines in adult mice. These mutants show hyperactive behavior and increased response to startle, correlating with the presence of abnormal myelin (Mayes et al., 2013) . These results are consistent with the hypothesis that defects in myelinating cells contribute to phenotypes in Rasopathies.
Elevated Ras signaling through MEK/ERK can increase reactive oxygen species (ROS) and nitrogen species (Heimfarth et al., 2013) , and in CNPase;HRasG12V mice, nitric oxide (NO) mediates myelin decompaction (Mayes et al., 2013) ; HRasG12V-expressing WM showed elevated NO synthases (NOS) and ROS, and blockade of NOS rescued aberrant behavior and myelin compaction. NO signaling inhibition also rescued myelin decompaction caused by inactivation of the Ras-GTP inhibitor Nf1 in oligodendrocytes and, interestingly, blocking NO production rescued abnormally hyperactive Notch signaling . Cell-cell interactions through Notch signaling negatively regulate oligodendrocyte maturation and myelin wrapping (Wang et al., 1998; Watkins, Emery, Mulinyawe, & Barres, 2008) . While a direct link between RAS and Notch in mOLs has not been identified, in other systems multiple levels of crosstalk between these signaling pathways are known (Sundaram, 2005) . Ras-GTP can act upstream of Notch signaling and the Notch pathway can feedback to antagonize the Ras pathway (Baumgart et al., 2015) . Here, we aimed to delineate effects downstream of HRasG12V mutation in mature oligodendrocytes (mOLs).
A limitation of transgenic HRasG12V mice to model the CS brain is that transgenic expression of activated RAS often fails to accurately model disease, due to altered levels, timing and/or strength of activating alleles in specific cell types (Di Nicolantonio et al., 2008; Sarkisian et al., 2007; To et al., 2008) . For example, CNPase;HRasG12V was expressed early in development, in immature and mOLs, and lacks normal genomic regulation (Mayes et al., 2013) . To better mimic human HRasG12V mutation in CS, we conditionally substituted the endogenous WT HRas with the mutant HRasG12V (Chen et al., 2009) (IACUC). Mice were housed in a temperature-and humidity-controlled vivarium on a 12-hr light-dark cycle with free access to food and water. Adult (<8 weeks old) male and female mice were used for experimentation.
| Mouse strains
See description in Table 1 below. All mice were maintained on a C57Bl/6 background. Mice were genotyped by PCR as previously described (references in table 1).
| Tamoxifen injections
Tamoxifen (Sigma-Aldrich; 100 lL; 75 mg/kg of body weight) in sunflower seed oil was administered I.P. twice daily for four consecutive days. Treatment was performed at 8 week of age in littermate WT and mutant mice, of both sexes. No genotype-or sex-dependent changes in body weight were observed.
| Tissue processing
Mice were anesthetized and perfused with 0.9% saline followed by ice cold 4% paraformaldehyde. Tissues were removed, postfixed in 4% paraformaldehyde overnight, and sectioned using a vibratome (Leica) or transferred to 20% sucrose for subsequent frozen sectioning.
| Immunohistochemistry and antibodies
Cryostat or vibratome sections were processed for immunohistochemistry using antibodies for markers; Rabbit anti-pERK (1:200; Cell Signaling) and Mouse anti-APC (CC1 1:300, Calbiochem). Fluorescent secondary antibodies (donkey antirabbit conjugated to Cy3 and donkey antimouse conjugated to Cy5, Invitrogen, Carisbad, CA) were used at 1:300 dilution. Fluoromount G was used to mount fluorescent sections.
| Image analysis
Fluorescent images were captured on a Nikon C2 Confocal microscope using a 203 objective (23 Zoom for 403) with lasers (405, 488, 561 
| Myelin analysis
To quantify total decompaction, myelin sheaths were rated as compacted or decompacted, as defined by the presence or absence of fibers with disruption of the myelin sheath (i.e., decompacted 5 presence of areas with splitting of myelin lamellae). To measure severity of decompaction, we analyzed each quartile of each fiber (4 measurements per myelinated axon cross section), and report results as 1, 2, 3, or 4 quadrants showing decompaction (color coded in Figures 3-6 ). The g-ratio of myelinated fibers was obtained by dividing the diameter of each axon by the fiber diameter (300-500 axons/mouse, n 5 3-5 mice/genotype/condition), using ImageJ software. When a fiber was identified as compact or showed 4 quadrants decompacted, 1 measurement was collected for g-ratio. However, if a fiber showed 2 quadrants decompacted, then 2 measurements were collected, perpendicular to each other; if a fiber showed 1 or 3 quadrants decompacted, 4 measurements at 908 angles were collected for measurement of myelin thickness. Measurement was carried out by individuals blinded to sample identify and treatment.
| Flow cytometry
Adult murine brains were processed for flow cytometry as described (Robinson et al., 2014) . Flow cytometry was performed using FacsDiva software for acquisition on an LSR II flow cytometer. We used antibodies recognizing oligodendrocyte progenitors (PDGFRa 1:50; Millipore), and mOLs (GalC 1:100; Millipore). An ENZO Life Sciences kit was used to detect NO (ENZ-51013-200). Importantly, a positive control (L-arginine, a NOS substrate) and a negative control (C-PTIO, a NO scavenger) validated staining specificity for NO (Kalyanaraman et al., 2012) . Analysis was performed using FlowJo10 software. Compensation was carried out using positive and negative controls, as well as Fluorescence Minus One samples, which were dissociated forebrain cells incubated with all stains except the marker of interest, to allow for appropriate compensation.
| Drug treatments
Gamma secretase inhibitor (GSI; MRK-003) was prepared fresh weekly and dosed at 300 mg/kg in 0.5% methocel by oral gavage (Lewis et al., 2007; Sparey et al., 2005) . For histology, we dosed mice once weekly for 4 weeks, and sacrificed them 6 hr after the last dose (n 5 5 doses).
Fresh solution of L-NG-Nitroarginine Methyl Ester (L-NAME) at 0.4 mg/kg (100 mM in 13 PBS) was administered daily. For pathology and flow analysis, mice were injected intraperitoneally daily with 100 ml for 7 days and sacrificed 6 hr after the last dose. MEK inhibitor (PD0325901 from Pfizer) was made fresh weekly and dosed at 1.5 mg/kg in 0.5% methocel/0.2% Tween 80 by oral gavage. For histology, we dosed mice every day for 3 weeks.
| Statistical analysis
The minimal number of mice per statistically significant experiment was 3. Comparison between two groups used Student's t-tests with significance cutoff of p < .05. For comparison of three or more groups, one-way ANOVA followed by Tukey post hoc test with significance cutoff of p < .05. Linear regression of g-ratio versus axon diameter was performed using Graph Pad software. Doerflinger, Macklin, & Popko, 2003) . In these mice, tamoxifen treatment induces the expression of HRasG12V upon excision of the endogenous HRas ( Figure 1a ). Recombination using this
PlpCre driver targets 35% of mOLs in the Corpus Callosum (CC), and essentially no NG2 1 oligodendrocyte progenitors or GFAP 1 astrocytes are recombined (Koenning et al., 2012; Mayes et al., 2013) . Numerous studies indicate that diverse phenotypes are caused by varying levels of Ras-MAPK activation (Cox and Der, 2003; Serrano, Lin, McCurrach, Beach, & Lowe, 1997 ;pERK 1 cells indicates significantly increased ERK activation in oligodendrocytes of pRsG/1 (n 5 6 mice, unpaired t test, **p 5 .002) or pRsG/G (n 5 3 mice, unpaired t test, *p 5 0.034) mutants, as compared with WT mice (n 5 9 mice). All data are presented as the mean 6 SEM mutants, yet specific induction of hyperactive Ras was achieved in both Ras mutants.
| Constitutive HRas activation in mOLs decreases g-ratio
To study WM abnormalities after Ras activation, we analyzed the ultrastructure of axons and myelin in sagittal sections at the midline of the CC of RasG12V mutants using electron microscopy ( Figure 2a ). and pRsG/G mutants at 1 month (1 mo, n 5 3 mice per genotype) and 6 months (6 mo, pRsG/1 mice; n 5 5, pRsG/G mice; n 5 3 mice) posttamoxifen (****p < .0001), as compared with g-ratio in WT mice (n 5 6 mice). The g-ratio was further decreased in pRsG/1 and pRsG/G mutants at 6 months post-tamoxifen, as compared with pRsG/1 and pRsG/G mice 1 month after tamoxifen (#### p < .0001), respectively. (c, d) Scatterplots and linear regression of the axon diameter versus g-ratio from myelinated fibers in WT (black), pRsG/1 (pink), and pRsG/G (green) mice, 1 month (c), and 6 months (d) after tamoxifen treatment. The slopes of g-ratio versus axon diameter are similar in HRas mutants compared with WT mice at 1 mo (c, black arrow); however, small g-ratio in HRas mutants is associated to small diameter axons at 6 mo (d, black arrow vs. red arrow). (e) Evaluation of the diameter of myelinated axons shows significant decreases in pRsG/1 (n 5 3 mice, **p 5 .001) and pRsG/G (n 5 3 mice, ****p < .0001) 1 month after tamoxifen treatment, as compared with WT mice. One way ANOVA and Tukey's multiple comparisons test was used in the analyses. All data are presented as the mean 6 SEM an increased association of low g-ratio with small caliber axons was observed in both homozygous and hemizygous HRasG12V mutants as compared with WT mice ( Figure 2d ); indicating that small caliber axons contribute to progressive abnormal g-ratio, and/or axons shrink over time ( Figure 2b ). Myelinating cells regulate axon caliber (Cole, Messing, Trojanowski, & Lee, 1994; Colello, Pott, & Schwab, 1994) , so myelin defects caused by HRas activating mutation in mOLs might disrupt axon structure. In fact, quantification of myelinated axon diameter indicated a significant skew to decreased axon diameter in both pRsG/1
and pRsG/G mutants, as compared with WT ( Figure 2e ). As neurons whose axons project through the CC do not express the PlpCre allele (Koenning et al., 2012; Mayes et al., 2013) , change in axon diameter is likely to be secondary to disturbed myelin integrity (Cole et al., 1994; Colello et al., 1994) , thus we focused on the analysis of the myelin structure.
| Hyperactivation of HRas in mOLs results in myelin decompaction
The MAPK signaling pathway regulates numbers of myelin wraps as well as compaction of myelin in mOLs (Ishii et al., 2013 . We observed that myelin thickness was increased in (Figure 3a) . Therefore, the two parameters determining g-ratio,
axon diameter, and myelin thickness, were abnormal in HRas mutants.
Quantification of the fibers showing decompaction indicated a significant increase in the percent of myelin sheaths with decompaction in both RasG12V mutants 1 month after tamoxifen treatment, as compared with WT mice (Figure 3b ). This phenotype was sustained for at 
| Myelin decompaction is partially rescued by inhibition of MEK or NOS, and full rescue is achieved by the concomitant treatment in hemizygous HRas mutants
To gain insight into molecular mechanisms driven by HRas activating mutations that affect oligodendrocytes, we first evaluated the effect of blocking MEK, the major effector pathway downstream of Ras-GTP in Rasopathies. We analyzed myelinated fibers in the CC of mice treated with the blood brain barrier-permeable MEK inhibitor (MEKi) PD0325901, starting 1 month post-tamoxifen (Barrett et al., 2008) .
Administration of MEKi did not significantly change myelin decompaction in WT mice, although a trend toward increased decompaction was observed ( Figure 4a ). Likewise, no differences in g-ratio were observed between vehicle-treated WT and MEKi-treated mice (Figure 4b ). MEKi treatment slightly improved compaction in pRsG/1 mutants, as compared with vehicle-treated mutants, but this was not significant ( Figure   4a ). In contrast, MEKi significantly normalized g-ratio in pRsG/1, FIGU RE 4.
F IGURE 4 Myelin defects in pRsG/1 mutants are susceptible to MEK and NOS pharmacological inhibition. (a) Quantification of total fibers with myelin decompaction, and quadrants with decompaction (color code), in WT and pRsG/1 mutants subjected to the indicated pharmacological treatments 1 month posttamoxifen. No significant changes (but a trend toward increase) are observed in the percent of decompacted fibers in MEK inhibitor (MEKi)-treated WT (n 5 6), as compared with vehicle-treated WT mice (n 5 3, ns: not significant, p 5 .219). Vehicle-treated pRsG/1 mutants (n 5 3) show increased myelin decompaction, as compared with vehicle-treated WT mice (methocel for MEKi; **p 5 .002 and PBS for L-NAME; **p 5 .003). No significant changes (but a trend toward decrease) were observed in decompaction in pRsG/1 mutants treated with MEKi (n 5 3 mice), as compared with vehicletreated mutants (ns, p 5 0.261). Significantly decreased percent of decompacted fibers were observed in pRsG/1 mutants treated with L-NAME (n 5 4 mice, $ p 5 .030), and myelin compaction was fully rescued to WT levels by concomitant treatment with L-NAME and MEKi, as compared with vehicle-treated mutants (n 5 4 mice,
The g-ratio comparison of WT and pRsG/1 mutants subjected to the indicated pharmacological treatments 1 month post-tamoxifen (same cohort of mice as in panel a). No significant changes were observed in g-ratio of vehicle-treated versus MEKi-treated WT mice (ns, p 5 .996). Vehicle-treated pRsG/1 mutants show decreased g-ratio, as compared with WT mice (PBS or methocel ****p < .0001). Significantly increased g-ratio was observed in pRsG/1 mutants treated with MEKi ( #### p < .0001) or L-NAME ( $$$$ p < .0001), as compared with vehicle-treated mutants, respectively. Furthermore, increased g-ratio was observed in pRsG/ 1 mutants concomitantly treated with MEK and L-NAME ( however full recovery to WT levels was not achieved (Figure 4b ). (Figure 4c ). Therefore, we evaluated myelin defects in pRasG12V hemizygous mutants treated with L-NAME, an inhibitor of NOS, starting at 1 month post-tamoxifen. L-NAME treatment caused a significant decrease in the number of fibers with decompaction in the CC of pRsG/1 mice ( Figure 4a ) and a significantly increased g-ratio (Figure 4b ), as compared with vehicle-treated Ras mutants. However, neither myelin compaction nor g-ratio were fully restored to WT levels.
To determine whether the combination of NOS and MEK inhibition provides an additive benefit, we assessed myelin properties in pRsG/1 mutants treated with MEKi and L-NAME and found that pathologic myelin decompaction was abolished (Figure 4a ). In fact, under these conditions, myelin was more compact than in untreated WT CC, and g-ratio was increased over the levels observed in WT mice ( Figure   4b ); suggesting that basal MAPK-NO signaling contributes to the maintenance of normal compact myelin. Taken together, these data show that disturbed MAPK and NO signaling cooperate to disrupt myelin structure upon HRasG12V expression.
| Inhibition of notch signaling rescues myelin defects in hemizygous HRasG12V mutants
We recently reported that myelin defects in a model of NF1 Rasopathy (Figure 5a) . Similarly, no significant differences were found between the g-ratio of pRsG/1;pRBPJ and pRsG/1 mutants (Figure 5b) .
Upon Notch ligand binding, active NICD is released by the action of Gamma secretase. Therefore, inhibition of this enzyme prevents Notch signaling. As a secondary strategy to evaluate the Notch pathway contribution to abnormal myelin in pRasG12V mutants, we treated mice with GSI. Analysis of CC myelinated axons revealed a significant decrease in the number of fibers with decompaction ( Figure 5c ) and an increase in g-ratio (Figure 5d 
| Concomitant inhibition of notch signaling and MAPK or NO signal pathways fully rescues myelin abnormalities in HRasG12V mutants
Given that neither treatment with MEKi, nor treatment with L-NAME, fully rescued myelin compaction in pRsG/1 mutants, and that blocking both pathways fully rescued the phenotypes, we tested whether inhibition of Notch pathway leads to additive effects on myelin structure.
We evaluated myelinated axons in the CC of pRsG/1;pRBPJ double mutants after treatment with MEKi or L-NAME. The combination of inducible genetic Notch inactivation with MEKi treatment decreased myelin decompaction significantly, to levels observed in WT mice (Figure 6a) . Fiber g-ratio was significantly improved in pRsG/1;pRBPJ double mutants treated with MEKi as compared with vehicle-treated mice of the same genotype (Figure 6b ). However, this combination did not improve g-ratio more than MEKi treatment alone, possibly because noncell autonomous effects on axon diameter are not affected by pRBPJ mutation in mOLs (Figure 2c ).
Additionally, pRsG/1;pRBPJ double mutant mice treated with L-NAME showed improved myelin compaction (Figure 6c ). Furthermore, g-ratio improved to WT levels ( Figure 6d ). Overall, these data support the idea that myelin decompaction caused by increased levels of Ras- 
| D I SCUSSION
RAS regulators, RAS effectors, and RAS proteins themselves can be mutated in Rasopathies and are the subject of intensive research, with new mutations still being detected (Tidyman and Rauen, 2016) . Precisely how increases in active RAS-GTP impair brain function is still
| 1997 poorly understood. In CS, as in many Rasopathies, hyperactive Ras signaling can cause neurodevelopmental abnormalities, including cognitive impairment, autism spectrum disorders, and WM abnormalities. Here, we report that the Ras-activating mutation HRasG12V, conditionally expressed in the endogenous H-Ras locus, causes pathological myelin decompaction mediated by MAPK, NO, and Notch signaling.
Strong evidence supports the idea that overexpression of mutant RAS can result in altered localization and cellular responses, versus RAS-GTP activated physiologically (Di Nicolantonio et al., 2008; Quinlan, Quatela, Philips, & Settleman, 2008; Sarkisian et al., 2007) . This is thought to result because local regulatory elements control RAS expression and downstream effects within tissues .
Therefore, use of the HRasG12V in its endogenous locus should accurately mimic cell autonomous effects of the Costello mutation in OL.
Previously we reported myelin decompaction in a transgenic CNPHRasG12V model, in which HRasG12V is expressed in developing OPCs and oligodendrocytes (Mayes et al., 2013) . Our new study of HRasG12V induction in its endogenous locus in mOLs, confirms a role of hyperactive HRas in pathological myelin decompaction and, importantly, shows the onset of this phenotype in mature OLs of the adult mouse, rather than in developmental stages with lower potential for therapeutics. While HRasG12V is a rare mutation associated with severe manifestations in CS patients (Aoki et al., 2005) , experimental G12V mutation mimicked phenotypes found in models of the most common HRas mutation (G12VS; Rooney et al., 2016) .
Several studies using gain and loss of function models have shown that the RAS effectors ERK1 and ERK2 promote the establishment and maintenance of myelin thickness, regulating both the number of myelin wraps and the abundance of major myelin proteins (Fyffe-Maricich et al., 2011 Guardiola-Diaz et al., 2012; Ishii et al., 2013 ). In contrast, we show that HRasG12V expression in mOL causes myelin thickening due to pathological myelin decompaction, without an increase in the number of myelin lamellae. Myelin decompaction was also reported in the CNP-HRasG12V mouse model in which changes in expression of tight junction, not myelin, proteins were observed (Mayes et al., 2013) .
Differences in myelin phenotypes may be due to the mutants analyzed and their effects on levels of RAS activation. Mechanistically, Ras-GTP activation of ERK1/ERK2 activates feedback regulation that dampens (c) Significantly decreased percent of decompacted fibers was observed in GSI-treated pRsG/1 mutants, as compared with vehicle-treated pRsG/1 mice (*p 5 .011). (d) A significant increase in g-ratio was detected in GSI-treated mutants, as compared with pRsG/1 mice (ns, p < .0001). In all panels; WT values are shown for reference, One-way ANOVA and Tukey's multiple comparisons test were used, and data are presented as the mean 6 SEM or enhances Ras signaling (Rauch, Rukhlenko, Kolch, & Kholodenko, 2016) . For example, the Ras-MAPK negative regulator Sprouty 2, induced on growth factor stimulation through MAPK, is highly expressed in the brain, where it dampens the impact of MAPK pathway activation in germline-HRasG12V mutants. Strong activation of MEK/ ERK is observed in the liver of the same mice, where Sprouty2 is virtually absent (Chen et al., 2009) . This is important because high levels of Ras-MAPK activation mediate cell senescence and apoptosis, while lower levels alter cell proliferation and differentiation (Cox and Der, 2003; Serrano et al., 1997) . Therefore, differences in feedback regula- were rescued by blocking NO generation using L-NAME (Mayes et al., 2013) . In ex-vivo brain preparations, Ras signaling through MEK/ERK also increased ROS/nitrogen species, and NO protected oligodendrocytes through inhibition of nitrotyrosine-induced ERK phosphorylation (Heimfarth et al., 2013) . At higher levels, NO can be toxic; suppressing myelin gene transcription, translation of myelin proteins (Jana and Pahan, 2013) , and promoting apoptosis (Li, Vana, Ribeiro, & Zhang, 2011) . In pRsG/1 mOLs, while inhibition of NO production decreased myelin decompaction, additionally targeting MEK was able to fully The g-ratio was significantly increased in MEKi-treated pRsG/1;pRBPJf/f mutants, as compared with vehicle-treated pRsG/1 mice (****p < .0001); however, the g-ratio was still significantly lower than those in WT mice (**p 5 .007). (c) Significantly decreased myelin decompaction was observed in pRsG/1;pRBPJf/f mice treated with L-NAME (n 5 3 mice), as compared with pRsG/1 mice (n 5 6 mice, *p 5 .021), and the values of decompaction were not significantly different than those of WT mice (ns, p 5 .888). (d) The g-ratio was significantly increased in L-NAME-treated pRsG/1;pRBPJf/f mutants, as compared with vehicle-treated pRsG/1 mice (****p < .0001), and g-ratio was not different from those of WT mice (ns, p 5 .057). In all panels, One-way ANOVA and Tukey's multiple comparisons test was used and data are presented as the mean 6 SEM rescue the myelin phenotype. Why both inhibitors are necessary in pRsG/1 mOLs remains unclear; it may result from vertical inhibition (e.g., the additive impact of blocking two members of the same signaling pathway) and/or from blocking pathway crosstalk.
In mOLs lacking the Nf1 Rasopathy gene, thereby activating RAS-GTP, NO links MAPK and Notch signaling (L opez-Ju arez et al., 2017).
Our data support a role for Notch signaling in mOLs, but in HRasG12V mOL the evidence is less robust than for the Nf1 model. Thus, while we demonstrate a trend toward improvement in myelin compaction in HRasG12V mice lacking Rbpj, the effect is not significant (unlike in the Nf1 setting). Additionally, given that gamma secretase has at least 90 substrates, the effects of GSI, while significant, cannot be taken as spe- Relationships between MEK-NOS-Notch pathways controlling normal and pathological myelin in a cell-autonomous manner are likely to be complex, and future studies will need to consider titering levels of response to optimize inhibitor effects in specific settings. Furthermore, noncell-autonomous activation of these pathways seems to add complexity to the system. Recombination is elicited by the PlpCreER driver in about 35% of mature carpus callosum oligodendrocytes (Koenning et al., 2012; Mayes et al., 2013) . In contrast, decompaction is observed in 60-70% of myelinated fibers, making it unlikely that only recombinant oligodendrocytes show abnormal myelin. In previous studies (Mayes et al., 2013 , as well as in this study, we show data supporting the idea that noncell-autonomous effects are mediated at least in part by a diffusible signal, NO.
In summary, MEK, NOS, and GSIs each partially rescue aberrant myelin decompaction in a CS Rasopathy model. It will be interesting to determine whether myelin alterations are present in CS patients, in whom many (in somatic mosaic patients) or all (in germline heterozygotes) brain cells are heterozygous for HRAS activating mutations.
Lastly, clinical trials are ongoing in many disorders in which MAPK, NO, and Notch signals are targeted/impacted; therefore, in the case of Rasopathies, treatment trials using inhibitors of these pathways are feasible.
